Guardant Health Loses Legal Challenge Over DNA Sequencing Patent

Key Facts

Guardant Health lost a legal challenge regarding a patent related to DNA sequencing technology. Seeking Alpha reported that the US Patent and Trademark Office's Patent Trial and Appeal Board rejected the challenge brought by the company against a patent held by TwinStrand Biosciences and the University of Washington.

The dispute involves technology for lowering errors in DNA sequencing, and the ruling represents a setback in the company's intellectual property litigation. In the equity markets, GH closed at $162.99 on October 14, 2026, having traded between a day low of $159 and a high of $166.16 during that session.